FDA Approves Sun Pharma’s Leqselvi for Treating Adults with Severe Alopecia Areata

Leqselvi is classified as a novel oral Janus Kinase inhibitor that targets JAK1 and JAK2 pathways, thought to be involved in the autoimmune response that leads to alopecia areata.